Polymorphisms inside MicroRNAs and MicroRNA Target Sites Predict Clinical Outcomes in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy

摘要: Purpose: Recent evidence indicates that small noncoding RNA molecules, known as microRNAs (miRNAs), are involved in cancer initiation and progression. We hypothesized genetic variations miRNAs miRNA target sites could be associated with the efficacy of androgen-deprivation therapy (ADT) men prostate cancer. Experimental Design: systematically evaluated 61 common single nucleotide polymorphisms (SNPs) inside a cohort 601 advanced treated ADT. The prognostic significance these SNPs on disease progression, cancer-specific mortality (PCSM) all-cause (ACM) after ADT were assessed by Kaplan–Meier analysis Cox regression model. Results: Four, seven, four significantly PCSM, ACM, respectively, univariate analysis. KIF3C rs6728684, CDON rs3737336, IFI30 rs1045747 genotypes remained significant predictors for progression; PALLD rs1071738, GABRA1 rs998754, SYT9 rs4351800 PCSM; predictor ACM multivariate models included clinicopathologic predictors. Moreover, strong combined genotype effects progression PCSM also observed. Patients greater number unfavorable had shorter time to worse survival during ( P trend Conclusion: have potential value improve outcome prediction patients receiving Clin Cancer Res; 17(4); 1–9. ©2010 AACR .